Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.53 |
| ▸ | LPL | P06858 | 6/20 | 0.53 |
| ▸ | F11 | P03951 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572162 | 0.88 | CA1 (0.60) | CA1CA2CA9LIPGLPL | |
| SCHEMBL16881568 | 0.85 | CA1 (0.57) | CA1CA2CA9LIPGLPL | |
| SCHEMBL3520098 | 0.84 | CA1 (0.56) | CA1CA2CA9LIPGLPL | |
| SCHEMBL171732 | 0.82 | LIPG (0.53) | CA1CA2CA9LIPGLPL | |
| SCHEMBL21197913 | 0.82 | CA1 (0.55) | CA1CA2CA9LIPGLPL | |
| SCHEMBL15252314 | 0.82 | CA1 (0.55) | CA1CA2CA9LIPGLPL | |
| SCHEMBL3212986 | 0.81 | CA1 (0.54) | CA1CA2CA9LIPGLPL | |
| SCHEMBL30693702 | 0.81 | CA1 (0.70) | CA1CA2CA9LIPGLPL | |
| SCHEMBL169651 | 0.80 | PRMT5 (0.58) | CA1CA2CA9LIPGLPL | |
| SCHEMBL5675802 | 0.80 | NPC1 (0.62) | CA1CA2CA9LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| CN-112608320-B | Piperidine compound and preparation method and medical application thereof | 中国药科大学 | 2023-03-17 | — | — | CN | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| EP-2385832-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | Curis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8040979-B2 | Generating a phase value for a complex signal | INFINEON TECHNOLOGIES AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | CA1 2921/4885CA2 2979/4885CA9 3587/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | CA1 2909/4885CA2 2940/4885CA9 3574/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | CA1 4738/4885CA2 4865/4885CA9 4117/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | CA1 2921/4885CA2 2979/4885CA9 3587/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | CA1 2909/4885CA2 2940/4885CA9 3574/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | CA1 2909/4885CA2 2940/4885CA9 3574/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | CA1 1953/4885CA2 1863/4885CA9 1091/4885 |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CA1 4587/4885CA2 3802/4885CA9 4203/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | CA1 3686/4885CA2 2081/4885CA9 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.